Insulin, a blood-sugar regulating hormone, plays a vital role in the entire treatment of diabetes. Patients have to use one of the available insulin delivery devices to access an insulin dose. The global insulin delivery devices market is on the spike, and is estimated to climb up in terms of revenues, reaching US$ 14.09 Bn by 2020 end, up from US$ 9.39 Bn in 2014. The overall growth rate will be healthy, reflected through a CAGR of around 7%, over the forecast period 2014-2020.
Key Market Dynamics
Growing prevalence of obesity and diabetes across the globe remains the key driver to foster the market for insulin delivery devices. Technological advances in these devices, coupled with rising patient awareness about diabetes care are expected to be a few more key factors holding a positive impact on the market growth. Widespread availability of various insulin delivery devices, such as insulin pens, syringes, pumps, and jet injectors, will also fuel the demand for insulin delivery devices over the forecast period. Increasing awareness programs and campaigns about diabetes and its complications, long-term implications, and treatment will provide a strong impetus to the demand for insulin delivering devices.
A few of the major trends in the global insulin delivery devices market are artificial pancreas and home infusion therapy. Cost-intensive insulin analog will however remain a major challenge to the market growth. Moreover, complication and risks associated with the delivery of insulin are also foreseen to restrain the demand for insulin delivery devices.
Based on the type of device, the global insulin delivery devices market is segmented into insulin syringes, insulin pens, insulin pumps, and insulin jet injections. While insulin syringes are user-friendly and self-administrable, insulin pens are compact in size and can be prefilled or reusable. Insulin jet injections are needleless, whereas insulin pumps are easily wearable by patients. Each of the device type has a unique attribute; however insulin pumps are projected to be a key segment driving major revenues to the market. The introduction of advanced insulin delivery devices, such as portable insulin pumps, will propel the market for insulin pumps in the next few years.
Geographical analysis bifurcates the global insulin delivery devices market five key gerions, including North America (the U.S., Canada, and rest of North America), Latin America (Brazil and rest of Latin America), Europe (the U.K., France, Italy, Spain, and rest of Europe) , Asia (China, Japan, India, and rest of Asia), and rest of the world. North America will maintain the leading market position, followed by Europe and Asia. The U.S. is likely to remain a larger market in North America, compared to Canada. While Europe will hold a sizeable market share, Asia will witness the fastest growth during the forecast period. The growth of Asian market is attributed to exploding population and growing geriatric as well as diabetic population. The market in Latin America is expected to witness increased sales, as some of the leading companies are expanding their manufacturing and R&D plants in this region.
Key Market Players
Some of the key players in the global insulin delivery devices market are Abbott Laboratories, Novo Nordisk A/S, Eli Lilly and Company, Medtronic, Inc., Sanofi, Becton, Dickinson and Company, and F. Hoffmann-La Roche, Ltd. Other notable companies include B. Braun Melsungen AG, Animas Corporation, Ypsomed Holding AG and Insulet Corporation. Most of these leading companies are constantly striving to introduce new, superior products to gain a competitive edge and empower theor positions in the global marketplace.
The global insulin delivery devices market report provides in-depth analysis and estimation of the insulin delivery devices market from 2014 to 2020, considering 2014 as the base year for calculation of all the market values. Additionally, data pertaining to current market dynamics, including market drivers, restraints, trends, recent developments, and upcoming opportunities in the market, has been provided in the global insulin delivery devices market report. The drivers section elaborates key factors that may bolster the market growth during the forecast period, whereas the restraints section provides an extensive analysis of some important factors that are anticipated to negatively influence the market growth.
The next part of the report offers value-added information on the latest trends in the global insulin delivery devices market and the upcoming opportunities that may prove to be profitable for stakeholders in the market, over the aforementioned forecast period. The report further bifurcates the market into various segments based on the type of insulin delivery device. There are four key segments, which are further sub-segmented. Each of them is exhaustively studied, examined, and elaborated to reveal the consumption pattern, growth rates, market shares, and growth prospects. The next section is of regional analysis based on the geography. The report assesses all regional markets with equal emphasis and helps to understand their individual growth dynamics along with potential opportunities in each of them.
Some of the major players operating in the market are Abbott Laboratories, Novo Nordisk A/S, Eli Lilly and Company, Medtronic, Inc., Sanofi, Becton, Dickinson and Company, and F. Hoffmann-La Roche, Ltd. The global insulin delivery devices market report’s key market players section provides in-depth profiles of these key companies on the basis of attributes such as company overview, recent developments, growth strategies, sustainability, financial overview, and estimated market share.
To deduce the global insulin delivery devices market size, the report considers various aspects based on secondary research. Furthermore, key data points such as region-wise split and market split by product type, vehicle type, and distribution channel; and qualitative inputs from primary respondents have been incorporated to arrive at appropriate market estimates. The forecast presented in the report assesses the total revenue generated and expected revenue contribution in the global insulin delivery devices market.
The report begins with sizing the market in terms of value and volume for the base year, which forms the basis for forecasting how the market is anticipated to take shape in the near future. Given the characteristics of the market, gathered data is triangulated via different analysis based on supply side and demand side drivers and other key dynamics of the global insulin delivery devices market. To develop the market forecast, Persistence Market Research has also conducted a factor analysis to understand the impact of various forces/factors on the target market. The report provides forecasts not only in terms of CAGR but also presents a detailed analysis based on key parameters such as Year-on-Year (Y-o-Y) growth to understand market predictability and to identify the right opportunities.
Another key feature of this report is an analysis of the global insulin delivery devices market and the corresponding revenue forecast in terms of absolute dollar opportunity, usually overlooked while forecasting the market. However, absolute dollar opportunity is critical in assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales perspective in the global insulin delivery devices market. Further, to understand key segments in terms of their growth and overall global insulin delivery devices market performance, Persistence Market Research has developed a market attractiveness index to help providers identify existing market opportunities in the global insulin delivery devices market.
Some of the major players operating in the market:
These key market players have been profiled on the basis of attributes such as company overview, recent developments, growth strategies, sustainability and financial overview.